Neurocrine Biosciences Inc. (NBIX)
NASDAQ: NBIXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NBIX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $15.24B
- P/E (TTM)
- 22.34
- Forward P/E
- 12.24
- EPS (TTM)
- $6.74
- Dividend yield
- None
- 52-week range
- 122.14 – 186.12
- Day range
- 150.24 – 158.26
- Volume / Avg
- 1.59M / 1.34M
- Beta
- —
- Shares outstanding
- 101.22M
52-week range
NBIX stock today
On Nov 20, NBIX ended the session at $150.57, shedding $6.02 (3.84%), versus the S&P 500's 3.70% decline. Shares are 19.1% below their 52-week high of $186.12, set on Jul 30, 2026 and 23.3% above the 52-week low of $122.14, in the middle of the past year's range. NBIX is up 6.2% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 6.2%.
At 22.3x trailing earnings, Neurocrine Biosciences trades below the peer-group median of 26.6x. Its forward P/E of 12.2x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Neurocrine Biosciences
Company profileNeurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Kyle W. Gano Ph.D.
- Headquarters
- San Diego, CA
- Employees
- 2,500
- IPO year
- 1996
- Website
- neurocrine.com
Financial highlights
Full financialsIn fiscal 2025, Neurocrine Biosciences generated $2.86 billion in revenue, up 21.4% from fiscal 2024, its 9th consecutive year of revenue growth. Net income was $478.6 million (+40.2% year over year), for a net margin of 16.7% versus a median of 13.2% in the prior 5 years. Gross margin was 98.2% (down from 98.6%) and operating margin 21.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| Growth | +21.45% | +24.81% | +26.76% | +31.34% | +8.38% |
| Net income | $478.60M | $341.30M | $249.70M | $154.50M | $89.60M |
| EPS (diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
Analyst forecast
ForecastConsensus (28 analysts)
strong_buy
Avg. price target
$208.54+38.50%
- Strong buy 4
- Buy 20
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $2.04 vs $1.95
- Surprise
- +4.62%
NBIX news
All NBIX news- Neurocrine Biosciences (NBIX) is a Top-Ranked Momentum Stock: Should You Buy?Nasdaq
- Neurocrine Biosciences, Inc. (NBIX) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Why Neurocrine Biosciences (NBIX) is a Top Growth Stock for the Long-TermNasdaq
- NBIX or GRDN: Which Is the Better Value Stock Right Now?NasdaqNBIX, GRDN
- Looking for a Growth Stock? 3 Reasons Why Neurocrine (NBIX) is a Solid ChoiceNasdaq
- All You Need to Know About Neurocrine (NBIX) Rating Upgrade to BuyNasdaq
- NBIX vs. GRDN: Which Stock Is the Better Value Option?NasdaqNBIX, GRDN
- Wall Street Analysts See a 25.53% Upside in Neurocrine (NBIX): Can the Stock Really Move This High?Nasdaq
Neurocrine Biosciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EXELExelixis Inc. | 64.63 | -1.82% | $15.77B | vs NBIX |
| TECHBio-Techne Corp | 72.67 | -0.04% | $11.42B | vs NBIX |
| RGENRepligen Corporation | 163.81 | -3.81% | $10.47B | vs NBIX |
| HALOHalozyme Therapeutics Inc. | 91.35 | -1.82% | $10.41B | vs NBIX |
| BNTXBioNTech SE ADR | 80.96 | -0.52% | $20.07B | vs NBIX |
| QGENQiagen N.V. | 49.30 | -0.66% | $10.18B | vs NBIX |
| KYMRKymera Therapeutics Inc. | 115.31 | -3.42% | $9.84B | vs NBIX |
| KRYSKrystal Biotech Inc. | 308.89 | -2.19% | $9.15B | vs NBIX |
Indexes, lists and sector
Neurocrine Biosciences stock FAQ
What is Neurocrine Biosciences's stock price today?
NBIX last traded at $150.57 as of Nov 20, 4:00 PM EST, down 3.84% on the day. Prices are delayed at least 15 minutes.
What is NBIX's P/E ratio?
NBIX trades at a trailing P/E ratio of 22.34 and a forward P/E of 12.24, compared with a median of 26.6 for its closest peers.
Who is Neurocrine Biosciences's CEO?
Mr. Kyle W. Gano Ph.D. is the chief executive officer of Neurocrine Biosciences Inc., which has about 2,500 employees.
What is the NBIX 52-week high?
The 52-week high for NBIX is $186.12 and the 52-week low is $122.14. The stock is currently 19.1% below its high.